MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Price, Forecast & Analysis
TSX:MDNA • CA58490H1073
MDNA.CA Key Statistics, Chart & Performance
The current stock price of MDNA.CA is 0.89 CAD. In the past month the price increased by 1.14%. In the past year, price decreased by -14.42%.
MDNA.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MDNA.CA. When comparing the yearly performance of all stocks, MDNA.CA is a bad performer in the overall market: 94.55% of all stocks are doing better.
MDNA.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA. The financial health of MDNA.CA is average, but there are quite some concerns on its profitability.
MDNA.CA Financial Highlights
Over the last trailing twelve months MDNA.CA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 54.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.58% | ||
| ROE | -134.89% | ||
| Debt/Equity | 0.01 |
MDNA.CA Forecast & Estimates
10 analysts have analysed MDNA.CA and the average price target is 3.09 CAD. This implies a price increase of 247.18% is expected in the next year compared to the current price of 0.89.
MDNA.CA Ownership
MDNA.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 578.612M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 400.807M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| COV | COVALON TECHNOLOGIES LTD | 14.72 | 44.468M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 36.395M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 31.632M | ||
| HEM | HEMOSTEMIX INC | N/A | 15.62M | ||
| MPH | MEDICURE INC | N/A | 11.588M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MDNA.CA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
MEDICENNA THERAPEUTICS CORP
2 Bloor St W., 7Th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Gino L. DeMichele
Employees: 18
Phone: 14166485555
MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ
Can you describe the business of MEDICENNA THERAPEUTICS CORP?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Can you provide the latest stock price for MEDICENNA THERAPEUTICS CORP?
The current stock price of MDNA.CA is 0.89 CAD. The price decreased by -2.2% in the last trading session.
Does MDNA stock pay dividends?
MDNA.CA does not pay a dividend.
What is the ChartMill rating of MEDICENNA THERAPEUTICS CORP stock?
MDNA.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a market capitalization of 74.23M CAD. This makes MDNA.CA a Micro Cap stock.